Identification of new P-glycoprotein inhibitors derived from cardiotonic steroids

Biochemical Pharmacology

Volumn 93, Issue 1, 2015, Pages 11-24

  Zeino, Maen ^a   Paulsen, Malte S ^b   Zehl, Martin ^c   Urban, Ernst ^c   Kopp, Brigitte ^c   Efferth, Thomas ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF VIENNA   (Austria)

Author keywords

Cardiotonic steroids; Chemotherapy; Multidrug resistance reversal; P glycoprotein

Indexed keywords

(3BETA,5BETA,11ALPHA,12ALPHA,14BETA,17BETA) 3,11 BIS(ACETYLOXY) 12,14 DIHYDROXYBUFA 20,22 DIENOLIDE; (3BETA,5BETA,11ALPHA,12BETA,14BETA,17BETA) 3,11,12 TRIS(ACETYLOXY) 14 HYDROXY ANDROSTANE 17 CARBOXYLIC ACID METHYL ESTER; (3BETA,5BETA,12BETA,17BETA) 3,12 BIS(ACETYLOXY) 11 OXOANDROSTANE 17 HYDROXYMETHYL ALPHA ACETATE; (3BETA,5BETA,14BETA,15ALPHA) 3 ACETYLOXY 14,15 DIHYDROXY ANDROST 16 ENE 17 CARBOXYLIC ACID METHYL ESTER; (3BETA,5BETA,14BETA,15BETA,17ALPHA) 3 ACETYLOXY 14,15 EPOXY ANDROSTANE 17 CARBOXYLIC ACID METHYL ESTER; 2 [7 (ACETYLOXY)TETRADECAHYDRO 2,4B DIMETHYL 1 OXO 2 PHENANTHRENYL]SUCCINIC ACID DIMETHYL ESTER; DOXORUBICIN; GLYCOPROTEIN P INHIBITOR; HYDROGEN; RESAZURIN; UNCLASSIFIED DRUG; VERAPAMIL; CARDIAC GLYCOSIDE; MULTIDRUG RESISTANCE PROTEIN;

ARTICLE; COMPUTER MODEL; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG CONFORMATION; DRUG CYTOTOXICITY; DRUG IDENTIFICATION; DRUG SCREENING; FLOW CYTOMETRY; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; HYDROGEN BOND; IC50; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; LEUKEMIA; LEUKEMIA CELL; MOLECULAR DOCKING; RESAZURIN ASSAY; ANTAGONISTS AND INHIBITORS; CELL LINE; CELL SURVIVAL; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; METABOLISM; PHYSIOLOGY; PROTEIN SECONDARY STRUCTURE; PROTEIN TERTIARY STRUCTURE;

CARDIAC GLYCOSIDES; CELL LINE; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; HUMANS; P-GLYCOPROTEIN; PROTEIN STRUCTURE, SECONDARY; PROTEIN STRUCTURE, TERTIARY;

EID: 84919771970     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2014.10.009     Document Type: Article

References (63)

1. Persidis A. Cancer multidrug resistance. Nat Biotechnol 1999;17:94-5.
2. Gillet JP, Efferth T, Remacle J. Chemotherapy-induced resistance by ATP-binding cassette transporter genes. Bba-Rev Cancer 2007;1775:237-62.
3. Choi CH. ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal. Cancer Cell Int 2005;5.
4. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002;2:48-58.
5. Efferth T. The human ATP-binding cassette transporter genes: from the bench to the bedside. Curr Mol Med 2001;1:45-65.
6. Aller SG, Yu J, Ward A, Weng Y, Chittaboina S, Zhuo R, et al. Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science 2009;323:1718-22.
7. Modok S, Mellor HR, Callaghan R. Modulation of multidrug resistance efflux pump activity to overcome chemoresistance in cancer. Curr Opin Pharmacol 2006;6:350-4.
8. Sharom FJ. ABC multidrug transporters: structure, function and role in chemoresistance. Pharmacogenomics 2008;9:105-27.
9. Singh S, Prasad NR, Chufan EE, Patel BA, Wang YJ, Chen ZS, et al. Design and synthesis of human ABCB1 (P-Glycoprotein) inhibitors by peptide coupling of diverse chemical scaffolds on carboxyl and amino termini of (S)-valine-derived Thiazole Amino Acid. J Med Chem 2014.
10. Eichhorn T, Efferth T. P-glycoprotein and its inhibition in tumors by phytochemicals derived from Chinese herbs. J Ethnopharmacol 2012;141:557-70.
11. Mann J. Natural products in cancer chemotherapy: past, present and future. Nat Rev Cancer 2002;2:143-8.
12. Krenn L, Kopp B. Bufadienolides from animal and plant sources. Phytochemistry 1998;48:1-29.
13. Newman RA, Yang PY, Pawlus AD, Block KI. Cardiac glycosides as novel cancer therapeutic agents. Mol Interv 2008;8:36-49.
14. Bagrov AY, Shapiro JI, Fedorova OV. Endogenous cardiotonic steroids: physiology, pharmacology, and novel therapeutic targets. Pharmacol Rev 2009;61:9-38.
15. Haux J, Klepp O, Spigset O, Tretli S. Digitoxin medication and cancer; case control and internal dose-response studies. BMC Cancer 2001;1:11.
16. Moreno YBL, Urban E, Gelbcke M, Dufrasne F, Kopp B, Kiss R, et al. Structure-activity relationship analysis of bufadienolide-induced in vitro growth inhibitory effects on mouse and human cancer cells. J Nat Prod 2013;76:1078-84.
17. Mijatovic T, Kiss R. Cardiotonic steroids-mediated Na+/K+-ATPase targeting could circumvent various chemoresistance pathways. Planta Med 2013;79:189-98.
18. Garrigues A, Nugier J, Orlowski S, Ezan E. A high-throughput screening microplate test for the interaction of drugs with P-glycoprotein. Anal Biochem 2002;305:106-14.
19. Ansbro MR, Shukla S, Ambudkar SV, Yuspa SH, Li LW. Screening compounds with a novel high-throughput ABCB1-mediated efflux assay identifies drugs with known therapeutic targets at risk for multidrug resistance interference. PloS one 2013;8.
20. Bushway PJ, Mercola M, Price JH. A comparative analysis of standard microtiter plate reading versus imaging in cellular assays. Assay Drug Dev Technol 2008;6:557-67.
21. van der Sandt ICJ, Blom-Roosemalen MCM, de Boer AG, Breimer DD. Specificity of doxorubicin versus rhodamine-123 in assessing P-glycoprotein functionality in the LLC-PK1, LLC-PK1: MDR1 and Caco-2 cell lines. Eur J Pharm Sci 2000;11:207-14.
22. Krishan A, Hamelik RM. Flow cytometric monitoring of fluorescent drug retention and efflux. Methods Mol Med 2005;111:149-66.
23. Wiench B, Eichhorn T, Korn B, Paulsen M, Efferth T. Utilizing inherent fluorescence of therapeutics to analyze real-time uptake and multi-parametric effector kinetics. Methods 2012;57:376-82.
24. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970;227:680-5.
25. Zhang FY, Du GJ, Zhang L, Zhang CL, Lu WL, Liang W. Naringenin enhances the anti-tumor effect of doxorubicin through selectively inhibiting the activity of multidrug resistance-associated proteins but not P-glycoprotein. Pharm Res 2009;26:914-25.
26. Bogush TA, Dudko EA, Bogush EA, Baryshnikov A. [Parameters of specific antibody interaction with P-gp in T-cell leukemia Jurkat cells]. Antibiotiki i khimioterapiia Antibiotics and chemoterapy [sic]/Ministerstvo meditsinskoi i mikrobiologicheskoi promyshlennosti SSSR 2009;54:3-9.
27. Huber K, Linde H, Meyer K. Psi-bufarenogin, a new bufadienolide from Ch'an Su and rearrangement product of arenobufagins as a note on the configuration of bufarenogins. Helvetica Chim Acta 1967;50:1994-2008.
28. Hofer P, Linde H, Meyer K. Konstitution Des Arenobufagins .23. Uber Krotengifte. Helvetica Chim Acta 1960;43:1950-5.
29. Linde H, Meyer K. Konstitution Des Resibufogenins Uber Krotengifte .17. Helvetica Chim Acta 1959;42:807-26.
30. Weiss J, Dormann SM, Martin-Facklam M, Kerpen CJ, Ketabi-Kiyanvash N, Haefeli WE. Inhibition of P-glycoprotein by newer antidepressants. J Pharm Exp Therap 2003;305:197-204.
31. Zeino M, Saeed ME, Kadioglu O, Efferth T. The ability of molecular docking to unravel the controversy and challenges related to P-glycoprotein-a well-known, yet poorly understood drug transporter. Invest New Drugs 2014.
32. Wiench B, Eichhorn T, Paulsen M, Efferth T. Shikonin directly targets mitochondria and causes mitochondrial dysfunction in cancer cells. Evidence-based Complem Alternative Med: eCAM 2012;2012:726025.
33. Watanabe T, Kokubu N, Charnick SB, Naito M, Tsuruo T, Cohen D. Interaction of cyclosporin derivatives with the ATPase activity of human P-glycoprotein. Br J Pharmacol 1997;122:241-8.
34. Ferreira RJ, Ferreira MJU, dos Santos DJVA. Molecular docking characterizes substrate-binding sites and efflux modulation mechanisms within P-glycoprotein. J Chem Inf Model 2013;53:1747-60.
35. Ambudkar SV, Kim IW, Xia D, Sauna ZE. The A-loop, a novel conserved aromatic acid subdomain upstream of the Walker A motif in ABC transporters, is critical for ATP binding. Febs Lett 2006;580:1049-55.
36. Klepsch F, Chiba P, Ecker GF. Exhaustive sampling of docking poses reveals binding hypotheses for propafenone type inhibitors of P-glycoprotein. Plos Comput Biol 2011;7.
37. Veal DA, Deere D, Ferrari B, Piper J, Attfield PV. Fluorescence staining and flow cytometry for monitoring microbial cells. J Immunol Methods 2000;243:191-210.
38. Poruchynsky MS, Ling V. Detection of oligomeric and monomeric forms of P-glycoprotein in multidrug-resistant cells (Vol. 33, Pg 4163, 1994). Biochemistry-Us 1994;33. 9032-.
39. Sagne C, Isambert MF, Henry JP, Gasnier B. SDS-resistant aggregation of membrane proteins: application to the purification of the vesicular monoamine transporter. Biochem J 1996;316(Pt 3):825-31.
40. Zhao Y, Hu J, Miao G, Qu L, Wang Z, Li G, et al. Transmembrane protein 208: a novel ER-localized protein that regulates autophagy and ER stress. PloS One 2013;8:e64228.
41. Lee YN, Chen LK, Ma HC, Yang HH, Li HP, Lo SY. Thermal aggregation of SARS-CoV membrane protein. J Virol Methods 2005;129:152-61.
42. McLane MW, Hatzidimitriou G, Yuan J, McCann U, Ricaurte G. Heating induces aggregation and decreases detection of serotonin transporter protein on western blots. Synapse 2007;61:875-6.
43. Nuti SL, Rao US. Proteolytic cleavage of the linker region of the human P-glycoprotein modulates its ATPase function. J Biol Chem 2002;277:29417-23.
44. Abbaszadegan MR, Cress AE, Futscher BW, Bellamy WT, Dalton WS. Evidence for cytoplasmic P-glycoprotein location associated with increased multidrug resistance and resistance to chemosensitizers. Cancer Res 1996;56:5435-42.
45. Senior AE, AlShawi MK, Urbatsch IL. The catalytic cycle of P-glycoprotein. FEBS Lett 1995;377:285-9.
46. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Ann Rev Pharmacol Toxicol 1999;39:361-98.
47. Dongping M. Identify P-glycoprotein substrates and inhibitors with the rapid, HTS P-glycoprotein-gloTM assay system. Promega Notes 2007;96:11-4.
48. Schwab D, Fischer H, Tabatabaei A, Poli S, Huwyler J. Comparison of in vitro P-glycoprotein screening assays: Recommendations for their use in drug discovery. J Med Chem 2003;46:1716-25.
49. Hall MD, Handley MD, Gottesman MM. Is resistance useless? Multidrug resistance and collateral sensitivity. Trends Pharmacol Sci 2009;30:546-56.
50. Johansson S, Lindholm P, Gullbo J, Larsson P, Bohlin L, Claeson P. Cytotoxicity of digitoxin and related cardiac glycosides in human tumor cells. Anti-cancer Drugs 2001;12:475-83.
51. Mahringer A, Karamustafa S, Klotz D, Kahl S, Konkimalla VB, Wang Y, et al. Inhibition of P-glycoprotein at the blood-brain barrier by phytochemicals derived from traditional Chinese medicine. Cancer Genom Proteom 2010;7:191-205.
52. Gozalpour E, Wittgen HG, van den Heuvel JJ, Greupink R, Russel FG, Koenderink JB. Interaction of digitalis-like compounds with p-glycoprotein. Toxicol Sci Off J Soc Toxicol 2013;131:502-11.
53. Taub ME, Podila L, Ely D, Almeida I. Functional assessment of multiple P-glycoprotein (P-gp) probe substrates: influence of cell line and modulator concentration on P-gp activity. Drug Metabol Disposit Biol Fate Chem 2005;33:1679-87.
54. Dayan G, Jault JM, Baubichon-Cortay H, Baggetto LG, Renoir JM, Baulieu EE, et al. Binding of steroid modulators to recombinant cytosolic domain from mouse P-glycoprotein in close proximity to the ATP site. Biochemistry-Us 1997;36:15208-15.
55. Bansal T, Jaggi M, Khar RK, Talegaonkar S. Emerging significance of flavonoids as P-glycoprotein inhibitors in cancer chemotherapy. J Pharm Pharm Sci 2009;12:46-78.
56. Shapiro AB, Ling V. Positively cooperative sites for drug transport by Pglycoprotein with distinct drug specificities. Euro J Biochem/FEBS 1997;250:130-7.
57. Liu R, Sharom FJ. Site-directed fluorescence labeling of P-glycoprotein on cysteine residues in the nucleotide binding domains. Biochemistry-Us 1996;35:11865-73.
58. Sharom FJ. The P-glycoprotein efflux pump: How does it transport drugs? J Membrane Biol 1997;160:161-75.
59. Coley HM. Overcoming multidrug resistance in cancer: clinical studies of p-glycoprotein inhibitors. Methods Mol Biol 2010;596:341-58.
60. Meng Z, Yang P, Shen Y, Bei W, Zhang Y, Ge Y, et al. Pilot study of huachansu in patients with hepatocellular carcinoma, nonsmall-cell lung cancer, or pancreatic cancer. Cancer 2009;115:5309-18.
61. Mechetner EB, Roninson IB. Efficient inhibition of P-glycoprotein-mediated multidrug resistance with a monoclonal antibody. Proc Natl Acad Sci USA 1992;89:5824-8.
62. Qin TJ, Zhao XH, Yun J, Zhang LX, Ruan ZP, Pan BR. Efficacy and safety of gemcitabine-oxaliplatin combined with huachansu in patients with advanced gallbladder carcinoma. World J Gastroenterol WJG 2008;14:5210-6.
63. Mekhail T, Kaur H, Ganapathi R, Budd GT, Elson P, Bukowski RM. Phase 1 trial of Anvirzel in patients with refractory solid tumors. Investigat New Drugs 2006;24:423-7.